title: Constant low rate of fungemia in norway, 1991 to 1996. The Norwegian Yeast Study Group.
abstract: Since 1991 information on yeast isolates from blood cultures has been recorded prospectively from all microbiological laboratories (5 university and 16 county or local hospital laboratories) in Norway (population, 4.3 million). From 1991 to 1996 a total of 571 episodes of fungemia in 552 patients occurred (1991, 109 episodes; 1992, 81 episodes; 1993, 93 episodes; 1994, 89 episodes; 1995, 98 episodes; and 1996, 101 episodes). The fungemia rates per 10,000 patient days were 0.29 in 1991 and 0.27 in 1996. The average rates for the years 1991 to 1996 were 0.37 for the university laboratories and 0.20 for the other laboratories. These rates are low compared to the rate (0. 76) in five Dutch university hospitals in 1995 and the rate (2.0) in Iowa in 1991. The four most frequently isolated species were Candida albicans (66%), Candida glabrata (12.5%), Candida parapsilosis (7.6%), and Candida tropicalis (6.4%). The incidences of both C. albicans (range, 63 to 73%) and C. glabrata (range, 8.4 to 15.7%) varied somewhat throughout this period, but no significant increase or decrease was noted. MICs of amphotericin B, flucytosine, and fluconazole were determined for 89% of the isolates. All were susceptible to amphotericin B, and only 29 (5.6%) strains had decreased susceptibility to flucytosine. All C. albicans isolates were susceptible to fluconazole. The percentage of yeast isolates with decreased susceptibility to fluconazole (MICs, >/=16 microgram/ml) did increase, from 9.6% in 1991 and 1992 to 12.2% in 1994, 16.1% in 1995, and 18.6% in 1996. This was largely due to increases in the percentages of resistant C. glabrata and Candida krusei strains in the last 2 years. Compared to the incidence in other countries, it is remarkable that Norway has such a low and constant incidence of fungemia. A possible reason for this difference might be a restricted antibiotic use policy in Norway.
authors.affiliation: Department of Bacteriology, National Institute of Public Health, 0462 Oslo, Norway. per.sandven@labmed.uio.no
authors.forename: P
authors.initials: P
authors.lastname: Sandven
authors.forename: L
authors.initials: L
authors.lastname: Bevanger
authors.forename: A
authors.initials: A
authors.lastname: Digranes
authors.forename: P
authors.initials: P
authors.lastname: Gaustad
authors.forename: H H
authors.initials: HH
authors.lastname: Haukland
authors.forename: M
authors.initials: M
authors.lastname: Steinbakk
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D016469:Fungemia / Q000453:epidemiology*; D005658:Fungi / Q000187:drug effects; D006801:Humans; D015994:Incidence; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009664:Norway / Q000453:epidemiology; D013997:Time Factors